ClinicalTrials.gg
CompletedNCT00938704Updated Oct 31, 2011Results posted

Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms

A Phase 4 interventional study of carboxymethylcellulose 0.5% +glycerin 0.9% and sodium hyaluronate 0.18% in Dry Eye Syndromes, sponsored by Allergan. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-31.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing carboxymethylcellulose in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. carboxymethylcellulose · Dry Eye Syndromes.

Enrollment
9th of 11
71 · median 80
Started
2009
with 1 other
Phase 4
11 of 12
2 open now
Registered
5th of 12
by date
Lead sponsor
5 of 12
Allergan

Among the 12 studies testing carboxymethylcellulose in Dry Eye Syndromes, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2009, is one of 11 in phase 4, and was the 5th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 12 studies testing carboxymethylcellulose in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About carboxymethylcellulose

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing carboxymethylcellulose in Dry Eye Syndromes, or all of them as a file.
02

Study summary

To compare the efficacy and safety of two non-preserved artificial tears, (carboxymethylcellulose 0.5%, + glycerin 0.9% vs. sodium hyaluronate 0.18%) eye drops for the treatment of the signs and symptoms of dry eye disease.

03

Conditions studied

  • Dry Eye Syndromes

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current use of an artificial tear product at least 2 times per day (e.g. for relief of dry eye symptoms of dryness).
  • Be likely to complete the entire course of study and to comply with appropriate instructions

Exclusion criteria

Exclusion Criteria:

  • Have undergone refractive surgery (e.g., cataract surgery, PRK, LASIK, or any surgery involving a limbal or corneal incision) within the last 12 months.
  • Have uncontrolled systemic disease
  • Are currently using, or have used within 14 days of study enrollment, any ocular medications other than artificial tears
  • Have anticipated contact lens wear during the study
  • Have an active ocular infection
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
71 participants (actual)

Study arms

  • Active comparator
    1

    carboxymethylcellulose 0.5%, glycerin 0.9%

    Drug: carboxymethylcellulose 0.5% +glycerin 0.9%

  • Active comparator
    2

    sodium hyaluronate 0.18%

    Drug: sodium hyaluronate 0.18%

Interventions

  • Drugcarboxymethylcellulose 0.5% +glycerin 0.9%

    Drug page: Carboxymethylcellulose

    To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.

    Also known as: Optive™ Sensitive

  • To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.

    Also known as: Vismed®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Ocular Surface Disease Index (OSDI) at Week 2

    Change from baseline in OSDI at Week 2. The OSDI consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (0=none of the time; 4=all of the time). The score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI scores are associated with greater severity. A negative number change from baseline indicates improvement.

    Time frame: Baseline, Week 2

Secondary outcomes

  1. Change From Baseline in Tear Breakup Time (TBUT) at Week 2

    Change from baseline in TBUT at Week 2. TBUT is defined as the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A positive number change from baseline indicates improvement.

    Time frame: Baseline, Week 2

  2. Change From Baseline in Corneal Staining at Week 2

    Change from baseline in corneal staining at Week 2. Staining of the cornea following ocular administration of fluorescein dye was graded using a 6-point scale (0=no staining, 5=diffuse staining). The higher the grade score, the worse the dry eye severity. A negative number change from baseline indicates improvement.

    Time frame: Baseline, Week 2

  3. Change From Baseline in Conjunctival Staining (Temporal) at Week 2

    Change from baseline in conjunctival (temporal) staining at Week 2. Staining of the conjunctiva following ocular administration of lissamine green dye was graded using a 6-point scale (0=no staining, 5=diffuse staining). The higher the grade score, the worse the dry eye severity. A negative number change from baseline indicates improvement.

    Time frame: Baseline, Week 2

  4. Change From Baseline in Conjunctival Staining (Nasal) at Week 2

    Change from baseline in conjunctival staining (nasal) at Week 2. Staining of the conjunctiva following ocular administration of lissamine green dye was graded using a 6-point scale (0=no staining, 5=diffuse staining). The higher the grade score, the worse the dry eye severity. A negative number change from baseline indicates improvement.

    Time frame: Baseline, Week 2

07

Results

Posted Oct 31, 2011

Participant flow

Participant flow — Overall Study
MilestoneCarboxymethylcellulose 0.5%, Glycerin 0.9%Sodium Hyaluronate 0.18%
Started3337
Completed3337
Not completed00

Outcome measures

PrimaryChange From Baseline in Ocular Surface Disease Index (OSDI) at Week 2

Change from baseline in OSDI at Week 2. The OSDI consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (0=none of the time; 4=all of the time). The score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI scores are associated with greater severity. A negative number change from baseline indicates improvement.

Time frame:
Baseline, Week 2
Reported as:
Mean · Scores on a Scale
Change From Baseline in Ocular Surface Disease Index (OSDI) at Week 2
Scores on a ScaleCarboxymethylcellulose 0.5%, Glycerin 0.9%Sodium Hyaluronate 0.18%
Baseline56.06 ± 13.4354.292 ± 13.100
Week 2-27.048 ± 17.87-28.303 ± 21.821
SecondaryChange From Baseline in Tear Breakup Time (TBUT) at Week 2

Change from baseline in TBUT at Week 2. TBUT is defined as the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A positive number change from baseline indicates improvement.

Time frame:
Baseline, Week 2
Reported as:
Mean · Seconds
Change From Baseline in Tear Breakup Time (TBUT) at Week 2
SecondsCarboxymethylcellulose 0.5%, Glycerin 0.9%Sodium Hyaluronate 0.18%
Baseline6.501 ± 1.735.914 ± 1.646
Week 22.919 ± 2.3882.538 ± 2.923
SecondaryChange From Baseline in Corneal Staining at Week 2

Change from baseline in corneal staining at Week 2. Staining of the cornea following ocular administration of fluorescein dye was graded using a 6-point scale (0=no staining, 5=diffuse staining). The higher the grade score, the worse the dry eye severity. A negative number change from baseline indicates improvement.

Time frame:
Baseline, Week 2
Reported as:
Mean · Scores on a Scale
Change From Baseline in Corneal Staining at Week 2
Scores on a ScaleCarboxymethylcellulose 0.5%, Glycerin 0.9%Sodium Hyaluronate 0.18%
Baseline1.818 ± 0.7791.608 ± 0.936
Week 2-1.288 ± 0.718-1.23 ± 1.090
SecondaryChange From Baseline in Conjunctival Staining (Temporal) at Week 2

Change from baseline in conjunctival (temporal) staining at Week 2. Staining of the conjunctiva following ocular administration of lissamine green dye was graded using a 6-point scale (0=no staining, 5=diffuse staining). The higher the grade score, the worse the dry eye severity. A negative number change from baseline indicates improvement.

Time frame:
Baseline, Week 2
Reported as:
Mean · Scores on a Scale
Change From Baseline in Conjunctival Staining (Temporal) at Week 2
Scores on a ScaleCarboxymethylcellulose 0.5%, Glycerin 0.9%Sodium Hyaluronate 0.18%
Baseline1.818 ± 0.9501.919 ± 1.010
Week 2-1.152 ± 0.972-1.216 ± 1.084
SecondaryChange From Baseline in Conjunctival Staining (Nasal) at Week 2

Change from baseline in conjunctival staining (nasal) at Week 2. Staining of the conjunctiva following ocular administration of lissamine green dye was graded using a 6-point scale (0=no staining, 5=diffuse staining). The higher the grade score, the worse the dry eye severity. A negative number change from baseline indicates improvement.

Time frame:
Baseline, Week 2
Reported as:
Mean · Scores on a Scale
Change From Baseline in Conjunctival Staining (Nasal) at Week 2
Scores on a ScaleCarboxymethylcellulose 0.5%, Glycerin 0.9%Sodium Hyaluronate 0.18%
Baseline1.758 ± 0.9022.000 ± 0.913
Week 2-1.061 ± 0.899-1.459 ± 1.043

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carboxymethylcellulose 0.5%, Glycerin 0.9%—0/33 (0%)0/33 (0%)
Sodium Hyaluronate 0.18%—0/37 (0%)0/37 (0%)

Baseline characteristics

Age Continuous
Age Continuous(years)Carboxymethylcellulose 0.5%, Glycerin 0.9%Sodium Hyaluronate 0.18%Total
Mean54.386 (20.277 to 87.485)48.787 (18.942 to 84.482)51.5865 (18.942 to 87.485)
Sex: Female, Male
Sex: Female, Male(Participants)Carboxymethylcellulose 0.5%, Glycerin 0.9%Sodium Hyaluronate 0.18%Total
Female232851
Male10919
08

Study locations

1 site
  • Ulm, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2009
First posted
Jul 14, 2009
Start
Jun 2009
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Oct 31, 2011
Last update
Oct 31, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00938704
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Jul 14, 2009
Start date
Jun 2009
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Oct 31, 2011
Last update
Oct 31, 2011

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboxymethylcellulose · Hyaluronic Acid

Start the discussion